JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Intra-Cellular Therapies (NASDAQ:ITCI), Inc. has moved one step closer to becoming a wholly owned subsidiary of Johnson & Johnson ... expansion to include major depressive disorder.

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

In a remarkable display of market confidence, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) stock has reached an all-time high, touching a price level of $128.01. According to InvestingPro data, the ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

If you’re on the fence about investing in Intra-Cellular Therapies, Inc. or Johnson & Johnson because you’re not ... which is in Phase 3 clinical trial for the treatment of major depressive disorder, ...